Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
Angela Dalia RicciAlessandro RizzoFabiola Lorena Rojas LlimpeFrancesca Di FabioDario de BiaseKarim RihawiPublished in: Cancers (2021)
Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 15-20% of gastric adenocarcinoma (GC) patients. In 2010, the landmark ToGA trial established the combination of trastuzumab plus chemotherapy as the first-line standard of care for HER2-positive GC patients with advanced disease. However, subsequent studies on HER2 targeted therapies in this setting failed to meet their primary endpoints, and not all HER2-positive GC patients benefit from targeted approaches. More recently, novel HER2-directed treatments have been investigated, including trastuzumab deruxtecan (T-Dxd); following the results of the DESTINY-Gastric01 study, T-Dxd received its first U.S. Food and Drug Administration (FDA) approval on 15 January 2021 for the treatment of adults with unresectable, locally advanced, or metastatic GC who have received a prior trastuzumab-based regimen. In this review, we discuss the current HER2-targeted treatments for GC in the advanced disease setting, mainly focusing on emerging new treatments and future research directions.
Keyphrases
- epidermal growth factor receptor
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- tyrosine kinase
- advanced non small cell lung cancer
- healthcare
- clinical trial
- peritoneal dialysis
- rectal cancer
- drug administration
- prognostic factors
- endothelial cells
- radiation therapy
- randomized controlled trial
- gas chromatography
- small cell lung cancer
- risk assessment
- current status
- phase ii study
- lymph node
- patient reported outcomes
- human health
- drug delivery
- health insurance